Knowledge of hereditary renal cancer syndromes: A pending issue for oncologists

Anti-Cancer Drugs

Volumn 22, Issue SUPPL. 1, 2011, Pages

  García Donas, Jesús ^a   Hernando, Susana ^a   Romero, Nuria ^a   Jara, Carlos ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Birt Hogg Dub ; carcinoma; chromophobe; collecting duct; hereditary; hereditary leiomyomatosis; hereditary papillary; renal clear cell; syndrome; Von Hippel Lindau

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; ELONGIN B; ELONGIN C; FORETINIB; FUMARATE HYDRATASE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METADRENALIN; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ACID BASE BALANCE; ANTIANGIOGENIC THERAPY; BIRT HOGG DUBE SYNDROME; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 17; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; EPIDIDYMIS; GENE MUTATION; GLUCOSE TRANSPORT; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; KIDNEY CYST; LEIOMYOMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OPHTHALMOLOGY; PANCREAS CYST; PAPILLARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VON HIPPEL LINDAU DISEASE;

BIRT-HOGG-DUBE SYNDROME; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LEIOMYOMATOSIS; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; SYNDROME; TREATMENT OUTCOME; VON HIPPEL-LINDAU DISEASE;

EID: 78650813897     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000390768.93282.65     Document Type: Review

References (39)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
2. Fong PC, Boss DS, Yap TA, Tutt A,Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134.
3. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma, and no renal disease: clinical implications. J Urol 1995; 154:2010-2014.
4. Walther MM, Reiter R, Keiser HR, Choyke PL, Venzon D, Hurley K, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel- Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999; 162:659-664.
5. Wong WT, Agron E, Coleman HR, Reed GF, Csaky K, Peterson J, et al. Genotype phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol 2007; 125:239-245.
6. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). Surgery 2007; 142:814-818.
7. Choo D, Shotland L, Mastroianni M, Glenn G, van Waes C, Linehan WM, Oldfield EH. Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg 2004; 100:480-487.
8. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163-2172.
9. Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel- Lindau disease. J Intern Med 1998; 243:541-545.
10. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel- Lindau tumor suppressor protein requires binding to complexes containing elongins, B/C and Cul2. Mol Cell Biol 1998; 18:732-741.
11. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the b-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-427.
12. Stolle C, Glenn GM, Zbar B, Humphrey JS, Choyke P, Walther M, et al. Improved detection of germ line mutations in the on Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998; 12:417-423.
13. Leung RS, Biswas SV, Duncan M, Rankin S. Imaging features of von Hippel- Lindau disease. Radiographics 2008; 28:65-79.
14. Chan CC, Collins AB, Chew EY. Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review. Retina 2007; 27:1-7.
15. Duffey BG, Choyke PL, Glenn GM, Grubb RL, Venzon D, Linehan WM, Walther MM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol 2004; 172:63-65.
16. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma TARGET study group. N Engl J Med 2007; 356:125-134.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-a in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
18. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon-a2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-2111.
19. Madhusudan S, Deplanque G, Braybrooke JP, Cattell E, Taylor M, Price P, et al. Antiangiogenic therapy for von Hippel-Lindau disease. JAMA 2004; 291:943-944.
20. Schuch G, de Wit M, Hö ltje J, Laack E, Schilling G, Hossfeld DK, et al. Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416. J Clin Oncol 2005; 23: 3624-3626.
21. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel- Lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009; 94:386-391.
22. Zbar B, Tory K, Merino MJ, Schmidt L, Glenn G, Choyke P, et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151:561-566.
23. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18:2343-2350.
24. Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, et al. A phase I study of foretinib: a multi-targeted inhibitor of c-MET and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010; 16:3507-3516.
25. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, et al. Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and Spectrum of Disease. Radiographics 2009; 29:741-754.
26. Srinivasan R, Choueiri TK, Vaishampayan U, Rosenberg JE, Stein MN, Logan T, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients with papillary renal carcinoma (PRC) [abstract]. J Clin Oncol 2008; 26:5103.
27. Birt AR, Hogg GR, Dubé WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977; 113:1674-1677.
28. Zbar B, Alvord WG, Glenn GM, Turner M, Pavlovich CP, Schmidt L, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11:393-400.
29. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002; 26:1542-1552.
30. Nickerson ML,Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2:157-164.
31. Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, Henske EP. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene 2009; 28:1594-1604.
32. Menko FH, van Steensel MA, Giraud S, Friis-Hansen L, Richard S, Ungari S, et al.; European BHD Consortium. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 2009; 10:1199-1206.
33. Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, et al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006; 26:1795-1806.
34. Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta derm Venereol 1973; 53:409-416.
35. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007; 31:1578-1585.
36. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germ line mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406-410.
37. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8:143-153.
38. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor-1a stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29:4080-4090.
39. Grubb RL III, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007; 177:2074-2080.